Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
Show more...
執行長
Ms. Natalie C. Holles
員工
31
國家
US
ISIN
US88427A1079
上市
0 Comments
分享你的想法
FAQ
Third Harmonic Bio 今天的股價是多少?▼
THRD 目前價格為 $5.38 USD,過去 24 小時下跌了 -0.09%。在圖表上更密切關注 Third Harmonic Bio 股票的表現。
Third Harmonic Bio 的股票代號是什麼?▼
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Third Harmonic Bio 的股票以代號 THRD 進行交易。
Third Harmonic Bio 的股價在上漲嗎?▼
THRD 股票較上週上漲 +0%,本月上漲 +0%,過去一年 Third Harmonic Bio 上漲 +51.55%。